ArticleCell biology and toxicology2025
Biosafety assessment of engineered CCL20 locked dimers in vivo.
Article in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Immune dysregulation by aberrant chemokine production underlies many diseases. Targeting chemokine receptors with small molecule inverse agonists, antagonists, or neutralizing antibodies has proven challenging due to non-specific effects and receptor upregulation. Locked dimers of chemokines, generated via cysteine substitutions to produce constitutively homodimeric molecules, offer a promising alternative for receptor-specific inhibition. This study evaluates the in vivo safety and dosing of an engineered CCL20 locked dimer (CCL20LD), which selectively binds CCR6 without inducing chemotaxis. The antagonist-like properties of CCL20LD make it a potential therapeutic for CCL20-CCR6 driven diseases. Daily 14-day subcutaneous administration of CCL20LD at doses previously shown to be therapeutically effective in preclinical models of psoriasis or psoriatic arthritis did not result in weight loss or immune suppression. CCL20LD administration had little to no effects on the complete blood count with differential, comprehensive metabolic panel, urinalysis, organ weights, or bone marrow progenitors. At single cell resolution, doses near 7.5mg/kg/day modestly disrupted T cell dependent B cell activation. While splenomegaly due to extramedullary hematopoiesis was observed at the highest tested dose, serum cytokine levels were largely unchanged. Combined, these findings indicate that selective targeting of CCR6 with an engineered CCL20 dimer is broadly safe in vivo, exhibiting a wide therapeutic window with minimal adverse or immunomodulatory effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.